Share on StockTwits

Keryx Biopharmaceuticals (NASDAQ:KERX) was down 14.4% on Thursday following a dissappointing earnings announcement, Stock Ratings Network reports. The stock traded as low as $12.11 and last traded at $12.16, with a volume of 5,387,264 shares trading hands. The stock had previously closed at $14.21.

The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 42.9% on a year-over-year basis.

A number of analysts have recently weighed in on KERX shares. Analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $24.00 to $30.00 in a research note on Friday, April 4th. They now have a “buy” rating on the stock. Separately, analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Wednesday, April 2nd. Finally, analysts at Mizuho raised their price target on shares of Keryx Biopharmaceuticals from $25.00 to $34.00 in a research note on Wednesday, April 2nd. They now have a “buy” rating on the stock. Nine equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $26.43.

The stock has a 50-day moving average of $14.94 and a 200-day moving average of $14.06. The company’s market cap is $1.118 billion.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.